These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 11956105)

  • 41. Enhanced phosphatidylinositol 3-kinase activity and high phosphorylation state of its downstream signalling molecules mediated by ret with the MEN 2B mutation.
    Murakami H; Iwashita T; Asai N; Shimono Y; Iwata Y; Kawai K; Takahashi M
    Biochem Biophys Res Commun; 1999 Aug; 262(1):68-75. PubMed ID: 10448070
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma.
    Drosten M; Hilken G; Böckmann M; Rödicker F; Mise N; Cranston AN; Dahmen U; Ponder BA; Pützer BM
    J Natl Cancer Inst; 2004 Aug; 96(16):1231-9. PubMed ID: 15316058
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Key role of Shc signaling in the transforming pathway triggered by Ret/ptc2 oncoprotein.
    Mercalli E; Ghizzoni S; Arighi E; Alberti L; Sangregorio R; Radice MT; Gishizky ML; Pierotti MA; Borrello MG
    Oncogene; 2001 Jun; 20(27):3475-85. PubMed ID: 11429694
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma.
    Cuccuru G; Lanzi C; Cassinelli G; Pratesi G; Tortoreto M; Petrangolini G; Seregni E; Martinetti A; Laccabue D; Zanchi C; Zunino F
    J Natl Cancer Inst; 2004 Jul; 96(13):1006-14. PubMed ID: 15240784
    [TBL] [Abstract][Full Text] [Related]  

  • 45. RET/PTC (rearranged in transformation/papillary thyroid carcinomas) tyrosine kinase phosphorylates and activates phosphoinositide-dependent kinase 1 (PDK1): an alternative phosphatidylinositol 3-kinase-independent pathway to activate PDK1.
    Kim DW; Hwang JH; Suh JM; Kim H; Song JH; Hwang ES; Hwang IY; Park KC; Chung HK; Kim JM; Park J; Hemmings BA; Shong M
    Mol Endocrinol; 2003 Jul; 17(7):1382-94. PubMed ID: 12738763
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Self-association of the transmembrane domain of RET underlies oncogenic activation by MEN2A mutations.
    Kjaer S; Kurokawa K; Perrinjaquet M; Abrescia C; Ibáñez CF
    Oncogene; 2006 Nov; 25(53):7086-95. PubMed ID: 16732321
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of Shc docking site on Ret tyrosine kinase.
    Arighi E; Alberti L; Torriti F; Ghizzoni S; Rizzetti MG; Pelicci G; Pasini B; Bongarzone I; Piutti C; Pierotti MA; Borrello MG
    Oncogene; 1997 Feb; 14(7):773-82. PubMed ID: 9047384
    [TBL] [Abstract][Full Text] [Related]  

  • 48. C-cell and thyroid epithelial tumours and altered follicular development in transgenic mice expressing the long isoform of MEN 2A RET.
    Reynolds L; Jones K; Winton DJ; Cranston A; Houghton C; Howard L; Ponder BA; Smith DP
    Oncogene; 2001 Jul; 20(30):3986-94. PubMed ID: 11494127
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Various mechanisms cause RET-mediated signaling defects in Hirschsprung's disease.
    Pelet A; Geneste O; Edery P; Pasini A; Chappuis S; Atti T; Munnich A; Lenoir G; Lyonnet S; Billaud M
    J Clin Invest; 1998 Mar; 101(6):1415-23. PubMed ID: 9502784
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype.
    Ito S; Iwashita T; Asai N; Murakami H; Iwata Y; Sobue G; Takahashi M
    Cancer Res; 1997 Jul; 57(14):2870-2. PubMed ID: 9230192
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Molecular diagnosis of multiple type 2 endocrine neoplasia].
    Amosenko FA; Pushkash K; Frilling A; Kozlova VN; Liubchenko LN; Kazubskaia TP; Brelysh KE; Gar'kavtseva RF; Kalinin VN
    Vestn Ross Akad Med Nauk; 2001; (2):34-7. PubMed ID: 11338505
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular mechanisms of RET activation in human cancer.
    Santoro M; Melillo RM; Carlomagno F; Fusco A; Vecchio G
    Ann N Y Acad Sci; 2002 Jun; 963():116-21. PubMed ID: 12095936
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Oncogenic RET receptors display different autophosphorylation sites and substrate binding specificities.
    Liu X; Vega QC; Decker RA; Pandey A; Worby CA; Dixon JE
    J Biol Chem; 1996 Mar; 271(10):5309-12. PubMed ID: 8621380
    [TBL] [Abstract][Full Text] [Related]  

  • 54. GDNF promotes tubulogenesis of GFRalpha1-expressing MDCK cells by Src-mediated phosphorylation of Met receptor tyrosine kinase.
    Popsueva A; Poteryaev D; Arighi E; Meng X; Angers-Loustau A; Kaplan D; Saarma M; Sariola H
    J Cell Biol; 2003 Apr; 161(1):119-29. PubMed ID: 12682085
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The multiple endocrine neoplasia type 2B point mutation alters long-term regulation and enhances the transforming capacity of the epidermal growth factor receptor.
    Pandit SD; Donis-Keller H; Iwamoto T; Tomich JM; Pike LJ
    J Biol Chem; 1996 Mar; 271(10):5850-8. PubMed ID: 8621456
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ligand stimulation of a Ret chimeric receptor carrying the activating mutation responsible for the multiple endocrine neoplasia type 2B.
    Rizzo C; Califano D; Colucci-D'Amato GL; De Vita G; D'Alessio A; Dathan NA; Fusco A; Monaco C; Santelli G; Vecchio G; Santoro M; de Franciscis V
    J Biol Chem; 1996 Nov; 271(46):29497-501. PubMed ID: 8910618
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification of SNT/FRS2 docking site on RET receptor tyrosine kinase and its role for signal transduction.
    Kurokawa K; Iwashita T; Murakami H; Hayashi H; Kawai K; Takahashi M
    Oncogene; 2001 Apr; 20(16):1929-38. PubMed ID: 11360177
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins.
    Iervolino A; Iuliano R; Trapasso F; Viglietto G; Melillo RM; Carlomagno F; Santoro M; Fusco A
    Cancer Res; 2006 Jun; 66(12):6280-7. PubMed ID: 16778204
    [TBL] [Abstract][Full Text] [Related]  

  • 59. RET oligonucleotide microarray for the detection of RET mutations in multiple endocrine neoplasia type 2 syndromes.
    Kim IJ; Kang HC; Park JH; Ku JL; Lee JS; Kwon HJ; Yoon KA; Heo SC; Yang HY; Cho BY; Kim SY; Oh SK; Youn YK; Park DJ; Lee MS; Lee KW; Park JG
    Clin Cancer Res; 2002 Feb; 8(2):457-63. PubMed ID: 11839664
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Distinct biological properties of two RET isoforms activated by MEN 2A and MEN 2B mutations.
    Rossel M; Pasini A; Chappuis S; Geneste O; Fournier L; Schuffenecker I; Takahashi M; van Grunsven LA; Urdiales JL; Rudkin BB; Lenoir GM; Billaud M
    Oncogene; 1997 Jan; 14(3):265-75. PubMed ID: 9018112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.